Investors got a lot of news yesterday with analyst downgrades for Apple, Revolve, Rain Therapeutics, and Intercept Pharmaceuticals. Apple was downgraded to Hold on downside risk to Q3 revenues, Revolve was downgraded on lack of near-term catalysts, Rain Therapeutics received downgrades following Phase 3 MANTRA data, and Intercept Pharmaceuticals was downgraded after FDA panel decision.
InvestingPro subscribers got these headlines in real time. Start your 7-day free trial to get a leg up on the market and always be the first to know.